Quick Answer
ALNYLAM PHARMACEUTICALS, INC. reported Stockholders Equity of $789.18 million for fiscal year 2025.
ALNYLAM PHARMACEUTICALS, INC. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $789.18M | +1076.3% |
| 2024 | $67.09M | +130.4% |
| 2023 | -$220.64M | -39.5% |
| 2022 | -$158.22M | -126.9% |
| 2021 | $588.20M | -42.1% |
| 2020 | $1.02B | -29.4% |
| 2019 | $1.44B | +10.5% |
| 2018 | $1.30B | -26.3% |
| 2017 | $1.77B | +92.0% |
| 2016 | $920.22M | -27.2% |
| 2015 | $1.26B | +35.1% |
| 2014 | $936.27M | +246.3% |
| 2013 | $270.35M | +101.7% |
| 2012 | $134.05M | +13.6% |
| 2011 | $118.00M | -25.4% |
| 2010 | $158.23M | -11.1% |
| 2009 | $177.97M | -12.0% |
| 2008 | $202.12M | +1.5% |
| 2007 | $199.17M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $233.89M | +622.9% | -6.7% |
| June 30, 2025 | $250.59M | +8270.6% | +117.1% |
| March 31, 2025 | $115.44M | +152.6% | +72.1% |
| December 31, 2024 | $67.09M | +130.4% | +107.4% |
| September 30, 2024 | $32.35M | +119.5% | +1154.9% |
| June 30, 2024 | -$3.07M | +99.2% | +98.6% |
| March 31, 2024 | -$219.27M | +15.4% | +0.6% |
| December 31, 2023 | -$220.64M | -39.5% | -33.0% |
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +1076.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2007–2025 period, ALNYLAM PHARMACEUTICALS, INC.’s stockholders equity has grown by 296.2% (from $199.17 million to $789.18 million).
- The most recent figure is from ALNYLAM PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: